INVEX Therapeutics Ltd Q4 FY26 Operational and Financial Update
Key points
- Expanded preclinical research program with Tessara Therapeutics evaluating Exenatide
- Cash and cash equivalents at quarter end were $4,016,000
- Operating cash outflows for the quarter were $501,000
Full summary
INVEX Therapeutics Ltd (ASX:IXC) has provided an operational and corporate update for the quarter ended 30 June 2026, as well as its Appendix 4C cash flow statement. The company announced the commencement of an expanded preclinical research program with Tessara Therapeutics, evaluating Exenatide and other GLP-1 receptor agonists in a three-dimensional Alzheimer's disease model. The program aims to benchmark Exenatide against a current GLP-1 agonist, evaluate combination regimens, and assess novel combinations. Financially, the company reported cash and cash equivalents of $4,016,000 at the end of the quarter, with operating cash outflows of $501,000, primarily due to increased research and development and administration costs.
Guidance
Operating cash outflows for Q4 FY26 were $501,000
Outlook
The company is optimistic about the potential of Exenatide in treating neurological conditions, particularly Alzheimer's disease, based on the results of the expanded preclinical research program.
Summary generated by a large language model. Please interpret with care.